drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy (CAR T)
drug_description
Autologous, genetically engineered chimeric antigen receptor T-cell therapy targeting HLA-G; administered as a single intravenous infusion to redirect patient T cells to recognize and kill HLA-G–expressing tumor cells and overcome HLA-G–mediated immune evasion.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a chimeric antigen receptor that recognizes HLA-G on tumor cells. CAR engagement activates T-cell cytotoxicity, cytokine release, and proliferation, enabling targeted killing of HLA-G–expressing tumors and overcoming HLA-G–mediated immune evasion.
drug_name
IVS-3001 (anti-HLA-G CAR-T cells)
nct_id_drug_ref
NCT05672459